AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06769984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTT11
Description: SCTT11 dose 1, dose 2, dose 3, dose 4
Study NCT06769984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose 1, dose 2, dose 3, dose 4
Study NCT06769906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized automatic coaching message for glycemic management and depressive symptom
Description: For 12 weeks, the intervention group will apply continuous glucose monitoring system and receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires.
Study NCT06766825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 1.5 mg/day
Description: Receive 1.5 mg/day of plitidepsin intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.
Study NCT06766825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.
Study NCT06766825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo and Plitidepsin 1.5mg/day
Description: Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during two treatment periods and receive plitidepsin 1.5mg/day during the last two treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.
Study NCT06765616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab Injection combined with radiotherapy and chemotherapy
Description: Radiotherapy regimen: SCRT short-term radiotherapy of 5 × 5Gy Immunotherapy regimen: Adebrelimab Injection 1200 mg or 20 mg/kg, iv., followed by administration on the 1st day of each subsequent chemotherapy cycle.~Chemotherapy regimen: CAPOX regimen (chemotherapy cycle d1, to chemotherapy cycle d14):~Oxaliplatin 130 mg/m2 iv d1~Capecitabine 1000 mg/m2 po bid d1\~14~Repeat every 3 weeks for 6 cycles~After completing 6 cycles of chemotherapy, the patient underwent TME surgery 2-3 weeks later.
Study NCT06766487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tongue resistance exercises
Description: The TRE program consisted of the following exercises:~Exercise 1: Tongue Protrusion and Retraction Against Resistance, Exercise 2: Anterior Tongue Protrusion and Retraction Against Resistance, Exercise 3: Middle Tongue Protrusion and Retraction Against Resistance, Exercise 4: Middle Tongue Elevation with Pharyngeal Sound Production, Exercise 5: Tongue Elevation and Posterior Sweeping, and Exercise 6: Saliva Swallowing with Lip Closure.
Study NCT06766487 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cheek bulging exercises
Description: Cheek bulging exercises involved a series of movements: Lip Closure: Participants began by closing their lips. Unilateral Cheek Bulging: They then bulged their right cheek, followed by relaxation and return to the initial position. This was repeated on the left side. Bilateral Cheek Bulging: Finally, participants bulged both cheeks simultaneously.
Study NCT06769737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interventional group#1
Description: The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) + 3 mcg of Dexmedetomidine HCL, Demexa®, 4mcg/ml (0.75 ml) total volume = 3.55 ml.~The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision. The Bromage score is a clinical scale used to determine motor block during regional anesthesia by evaluating lower limb movement: Grade 0: Full movement of hips, knees, and ankles (no block). Grade 1: Unable to lift the leg but can move knees and ankles (partial block). Grade 2: Unable to bend the knee but can move ankles (near-complete block). Grade 3: No movement in hips, knees, or ankles (complete block). Dermatomal coverage will be assessed simultaneously till it reaches the L1-L2 level. Also, The Ramsay Sedation Scale (RSS) will be used to evaluate the sedation depth, if any.
Study NCT06769737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interventional group#2
Description: The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) total volume = 2.8 ml.~The intravascular mixture consists of 0.5 mcg/kg of Dexmedetomidine HCL, Demexa®, and a maximum of 30 mcg diluted to 4 mcg/ml. According to body weight, the total volume is 7.5 ml or less and given using a syringe pump over 30 minutes. The anesthesiologist will start the infusion once the patient is positioned supine post-spinal anesthesia and has stable hemodynamics. The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision reaches grade 3: No movement in hips, knees, or ankles (complete block). The anesthesiologist will assess dermatomal coverage until it reaches the L1-L2 and calculate the Ramsay Sedation Scale (RSS) of the depth of sedation aiming for level 2: Patient is cooperative, oriented, and calm
Study NCT06766240 — intervention group
Intervention type: DEVICE
Intervention: MRI on lumbosacral spine
Description: MRI imaging on lumbosacral spine using Philips Achieva1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea1.5T MRI device (Siemens Healthineers, Germany). the sequences used are Axial T2W; Sagittal T1W, T2W, Sagittal STIR, Coronal STIR and post gadolinium if needed.
Study NCT06763757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy Program
Description: The Art Therapy Program consists of 12 weekly group sessions, each lasting 90 minutes, designed to improve emotional well-being and quality of life in solitary older adults. Participants engage in structured activities that include creating art (e.g., drawing and painting), observing and interpreting art pieces, and reflective discussions to explore personal emotions and experiences. The sessions are led by trained facilitators under the supervision of licensed occupational therapists. This intervention follows a thematic progression: initial sessions focus on building trust and self-expression, mid-sessions deepen emotional awareness, and final sessions culminate in a creative project reflecting the participant's personal growth. Unlike other interventions, this program is tailored specifically for older adults living alone, addressing their unique challenges of isolation and reduced social interaction.
Study NCT06763172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Description: Caffeine (200mg) will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
Study NCT06763172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose tablet will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
Study NCT06765538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video consultation
Description: Preanaesthetic videoconsultation
Study NCT06765018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Brush (Orabrush)
Description: Patients in this group uses the Tongue Brush (Orabrush) 2 times a day for a duration for 3-5 days until the follow-up-screening takes place.
Study NCT06520982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Norepinephrine
Description: Infused intra-arterially in a dose-response fashion
Study NCT06520982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isoproterenol
Description: Infused intra-arterially in a dose-response fashion
Study NCT06520982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetylcholine
Description: Infused intra-arterially in a dose-response fashion
Study NCT06520982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nitroprusside
Description: Infused intra-arterially in a dose-response fashion
Study NCT06520982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Estrogen
Description: Infused intra-arterially
Study NCT06768658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951
Description: TAK-951 subcutaneous injection.
Study NCT06768658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951 Placebo
Description: TAK-951 placebo-matching subcutaneous injection.
Study NCT06768385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Description: : It was performed under USG guidance using 30 ml of 0.25% bupivacaine with an 80 mm insulated peripheral block needle. Local anaesthetic was applied between the upper fascia of the transversus abdominus muscle and the fascia of the internal oblique muscle at the midpoint of the distance between the costal margin and the iliac crest in the midaxillary line under USG imaging guidance.
Study NCT06768385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracoabdominal nerve blockage with perichondrial approach (TAPA) block
Description: Under USG guidance, 20 ml of 0.25% bupivacaine was administered between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue at the level of the 9th and 10th ribs (arcus costarum) in the midclavicular line with an 80 mm insulated peripheral block needle. Then, 10 ml of 0.25% bupivacaine was injected into the upper fascia of the costochondral tissue and the lower fascia of the external oblique muscle. The block was performed by following the needle path in the ultrasound image.
Study NCT05698979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX INJECTION
Description: The patient will be treated with a single session with botulinum toxin A injections at the hospital, and the judgmental criteria will be assessed at 1, 3 and 6 months post injections.~The injections will be made in 4 injection points at the palmar or distal plantar fold, at the level of the neurovascular beams, 2h after topical anesthesia by lidocaine cream under occlusion, associated or not with nitrous oxide inhaled at the time of the injections (BOTOX® 100 U).~In the event of multiple lesions, a single limb is injected based on clinical severity (ulcer, gangrene) and ischemia parameters (lowest TCPO2).
Study NCT06768827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Oral Product
Description: Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
Study NCT06768827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactulose Oral Product
Description: Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
Study NCT06767631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: threedimensional freehand ultrasound and instrumented spasticity assessment
Description: To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.
Study NCT06765161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efgartigimod administration
Description: efgartigimod infusion
Study NCT06767956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GOLCADOMIDE
Description: Golcadomide (GOLCA, CC-99282) is an oral cereblon E3 ligase modulator (CELMoD®) agent with immunomodulatory and tumor cell-autonomous activities. It is a modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities.
Study NCT06767956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint inhibitor targeted therapy drug that blocks the PD-1 (programmed death receptor-1) pathway to help prevent cancer cells from hiding from the immune system, boosting the immune system's response.
Study NCT06767046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRAS-specific Autologous TCR-T cell injection
Description: Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection
Study NCT06769971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: 20mg/kg，IV infusion，Day1，Q3W
Study NCT06769971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10mg/kg，IV infusion，Day8，Q6W
Study NCT06769971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/kg，IV infusion，Day1-3，Q3W
Study NCT06769971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5，IV infusion，Day1，Q3W
Study NCT06028802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT Clock Tool measurement
Description: Ratio of CT attenuation measurements acquired from within the visible ischaemic lesion (or estimated location if not visible) ÷ CT attenuation measurements acquired from within the equivalent normal brain.
Study NCT06767592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-Kult Advanced
Description: Bio-Kult Advanced will be provided as capsules and can be stored at room temperature. Participants will be instructed to swallow two capsules in the morning and two capsules in the evening, with food.
Study NCT06768970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CARDIO® salmon oil
Description: CARDIO® is a natural salmon oil manufactured from the enzymatic hydrolysis of Norwegian Atlantic salmon. Salmon capsules contain a full spectrum omega- and non-omega marine fatty acids with naturally occurring astaxanthin.
Study NCT06087263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given by PO
Study NCT06366269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: traditional and electroacupuncture
Study NCT06366269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral management
Description: based on American urologic association guidelines
Study NCT04550169 — intervention group
Intervention type: OTHER
Intervention: Intensive Care Coordination
Description: Intensive care coordination will include:~* Discharge instructions and contacts for following up on care and treatment~* Referral information~* Appointment scheduling~* Medication instructions~* Intensive care coordination by a social worker, case manager, nurse, or care coordinator to connect Medical Assistance (MA) recipient to a primary care provider or to a managed care organization~* Information about other health and social resources, such as transportation and housing~* Sharing of information (discharge instructions, medication information, and care plan information) with managed care organization in which patients are enrolled, if applicable
Study NCT04858412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: β-hydroxy β-methyl butyrate (HMB) enriched amino acid
Description: β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.
Study NCT04858412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Balanced amino acid
Description: Balanced amino acid is the balanced mixture of the various essential amino acids.
Study NCT06465745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AltaValve System.
Description: Transcatheter Mitral Valve Replacement.
Study NCT06339580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volume-targeted non-invasive ventilation
Description: A target tidal volume is set on the ventilation device, and the device will then automatically adjust delivered pressures to reach this target tidal volume.
Study NCT05578586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem 1000 mg
Description: given as 6 or 3 infusions in 15 minues or 3 hours.
Study NCT05578586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 1000 mg
Description: given as 6 or 3 infusions in 15 minues or 3 hours.
Study NCT04302623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Upa Yoga program consisting of physical postures, breathing techniques, chanting, and meditation.
Study NCT05929235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-909
Description: FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.
Study NCT06342089 — intervention group
Intervention type: OTHER
Intervention: Type I diabetes milletus
Description: the exposure is type I diabetes milletus
Study NCT05151497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group:Halliwick + Método Watsu
Description: Carrying out the Ten Points Program through the Halliwick Concept, together with the Watsu Method through a series of relaxation maneuvers and mobilization of the body in float, and an immersion time of 15 minutes without doing physical activity in a pool at a temperature of 30ºC , to decrease spasticity of various muscles.
Study NCT05151497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group:Halliwick
Description: Exclusive use of treatment through the Halliwick Concept Ten Point Program, along with immersion in hot water to reduce spasticity in various muscles.
Study NCT05675852 — intervention group
Intervention type: OTHER
Intervention: 68-electrode electroencephalography with steady state visual evoked potentials
Description: Electroencephalography is registered through a 68-electrode electroencephalography while stimuli will be presented at the centre of the screen at a distance of 150cm.~The pattern of visual stimulation is based on the technique of steady state visual evoked potentials. These potentials consist of the presentation of a visual stimulus at a (relatively fast) periodic rate to produce an EEG signal over the occipital cortex exactly at the frequency of stimulation. By varying the value of a parameter of the stimulation (e.g. the contrast of the stimulus) varies. This variation makes it possible to determine the threshold value where an EEG response is perceived, and thus to evaluate visual parameters such as visual acuity, contrast sensitivity or recognition of more complex shapes.
Study NCT05515614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Targeted Fortification
Description: Mother's breast milk will be fortified in modular fashion based on the level of macronutrients (protein, carbohydrate, and fat) found from analysis using the Miris Human Milk Analyser. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. Mother's breast milk will be fortified in modular fashion. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. For lipid supplementation, safflower oil will be utilized. We will set our goal energy level between 110 - 135 kcal/kg/day, protein level between 3.5 - 4.5 g/kg/day, lipid level between 4.8 - 6.6 g/kg/day, and carbohydrate level between 11.6 - 13.2 g/kg/day. We will regard daily fluid volume to be between 150 to 180 mL/kg/day.
Study NCT05515614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enfamil Liquid Human Milk Fortifier
Description: Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier as per standard feeding protocol defined by LLUCH NICU manual.
Study NCT06366269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral management
Description: based on American urologic association guidelines
Study NCT06366269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: pelvic floor with biofeedback
Study NCT03390530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thyroxine
Description: 8 µg/kg/day divided into two doses intravenous every 12 hours
Study NCT03390530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05550363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexycu
Description: 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
Study NCT05550363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Vehicle
Description: Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg